

# Tafasitamab (Synonyms: MOR-208; XMAB5574)



Catalog Number: 176951

## Product name

Tafasitamab (Synonyms: MOR-208; XMAB5574)

## Specificity

Human CD19

## Antibody description

Anti-CD19 Antibody (Tafasitamab)

## Preparation

Recombinant expression and purified from CHO cells.

## Formulation

25mM histidine, 8% sucrose, 0.01% Tween 80, pH6.2

## Storage

Upon receipt, store immediately at -20°C for 24 months in lyophilized state. -80°C for 12 month after reconstitution. Avoid repeated freeze-thaw cycles.

## Clonality

Monoclonal


## Ig Type

IgG1

## Applications


ELISA

## Validations




## SDS-PAGE

Anti-CD19 Antibody (tafasitamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.



## SEC-HPLC

The purity of Anti-CD19 Antibody (tafasitamab) is 98.59%, determined by SEC-HPLC.



## Bioactivity: ELISA


Immobilized human CD19 (20 291) Protein, His Tag at 2 ug/mL can bind Anti-CD19 Antibody (tafasitamab), EC50=0.0904 ug/mL.

# Tafasitamab (Synonyms: MOR-208; XMAB5574)



Catalog Number: 176951

---



Bioactivity: FACS

Human CD19 HEK293 cells were stained with Anti-CD19 Antibody (tafasitamab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS,  $EC_{50}=0.085 \text{ ug/mL}$ .